Skip to main content
Clinical Trials/NCT02207322
NCT02207322
Completed
N/A

Randomized Study of a Targeted Inpatient Supportive Care Intervention in Patients Hospitalized for Hematopoietic Stem Cell Transplantation (HSCT)

Massachusetts General Hospital1 site in 1 country160 target enrollmentAugust 2014

Overview

Phase
N/A
Intervention
Not specified
Conditions
Complication of Transplant
Sponsor
Massachusetts General Hospital
Enrollment
160
Locations
1
Primary Endpoint
Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT) Score at Week-2
Status
Completed
Last Updated
last year

Overview

Brief Summary

The main purpose of this study is to assess whether early integration of palliative and supportive care services in care of patients hospitalized for hematopoietic stem cell transplantation (HSCT) can improve patients' and family caregivers' quality of life and mood.

Detailed Description

This research study is evaluating the impact of early involvement of supportive care team working with the transplant oncology team will have on the quality of life, symptoms, and mood of patients undergoing stem cell transplantation. The purpose of this research study is to find out whether introducing patients and families undergoing stem cell transplantation to the palliative care team that specializes in symptom management can improve the physical and psychological symptoms that patients and families experience during hospitalization for stem cell transplantation. The study will use a series of questionnaires to measure participant's and their caregivers' quality of life, physical symptoms, and mood. Study questionnaires will be completed in the hospital or clinic with assistance provided as needed

Registry
clinicaltrials.gov
Start Date
August 2014
End Date
August 2017
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

El-Jawahri, Areej,M.D.

Director MGH BMT Survivorship Program

Massachusetts General Hospital

Eligibility Criteria

Inclusion Criteria

  • Patients Eligibility Criteria:
  • Adult patients (≥18 years) with hematologic malignancy admitted to Massachusetts General Hospital for HSCT are eligible for the study.
  • Ability to speak English or able to complete questionnaires with minimal assistance required from an interpreter or family member.
  • Caregivers Eligibility Criteria:
  • Adult caregivers (\>18 years) of patients undergoing HSCT at MGH who agreed to participate in study.
  • A relative or a friend, identified by the patient who either lives with the patient or has in-person contact with him or her at least twice per week.
  • Ability to read questions in English or willing to complete questionnaires with the assistance of an interpreter.

Exclusion Criteria

  • Patients with prior history of HSCT.
  • Patients undergoing HSCT for a benign hematologic condition (myelodysplastic syndrome (MDS) is not considered a benign hematologic condition and patients with MDS are eligible for the study)
  • Significant uncontrolled psychiatric disorder (psychotic disorder, bipolar disorder, major depression) or other co-morbid disease (dementia, cognitive impairment), which the treating clinician believes prohibits informed consent or participation in the study.
  • Patients enrolled on other supportive care intervention trials.

Outcomes

Primary Outcomes

Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT) Score at Week-2

Time Frame: week-2

Compare quality of life (QOL) (FACT-BMT) scores at week-2 (day+5 for autologous, day +8 for myeloablative or reduced intensity allogeneic HSCT) adjusting for baseline QOL scores between the study arms. Score range 0-164 with higher scores indicating better quality of life

Secondary Outcomes

  • FACT-BMT Score at 3 Months(3 months)
  • FACT-BMT Score at 6 Months(6 Months)
  • Depression Symptoms at Week-2 Using the Hospital Anxiety and Depression Scale (HADS)(week-2)
  • Depression Symptoms at 6 Month Using the Hospital Anxiety and Depression Scale (HADS)(6 months)
  • Depression Symptoms at 3 Month Using the Hospital Anxiety and Depression Scale (HADS)(3 month)
  • Anxiety Symptoms at 6 Months Using the Hospital Anxiety and Depression Scale (HADS)(6 months)
  • Depression Scores Using Patient Health Questionnaire-9 (PHQ9) at Week-2(week 2)
  • Anxiety Symptoms at Week-2 Using the Hospital Anxiety and Depression Scale (HADS)(week-2)
  • Anxiety Symptoms at 3 Months Using the Hospital Anxiety and Depression Scale (HADS)(3 months)
  • Fatigue Scores (as Measured by FACT-Fatigue) at 3 Months(3-months)
  • Depression Scores Using Patient Health Questionnaire-9 (PHQ9) at 3 Months(3-month)
  • Depression Scores Using Patient Health Questionnaire-9 (PHQ9) at 6 Months(6-month)
  • Fatigue Scores (as Measured by FACT-Fatigue) at Week-2(week-2)
  • Symptom Burden (as Measured by the Edmonton Symptom Assessment Scale) at Week-2(week-2)
  • Patient-reported Post-Traumatic Stress Disorder (PTSD) as Measured by the PTSD Checklist at 6 Months(6-months)
  • Patient-reported Post-Traumatic Stress Disorder (PTSD) as Measured by the PTSD Checklist at 3 Months(3-months)

Study Sites (1)

Loading locations...

Similar Trials